EBVD and alternating MOPP/EBVD with or without localized field radiotherapy in advanced or unfavorably presenting Hodgkin's disease.
Enrico Maria Pogliani(Azienda Ospedaliera San Gerardo), Edmondo Cassi(University of Milan), P Marinoni, M Maioli, Chiara Butti(University of Milan), L Montalbetti, Fausto Rossini(University of Milan), Paolo Vanoli(University of Milan), Luca Baldini(University of Milan), C Confalonieri, O. Chiorboli, Anna Tosi(University of Padua), Sergio Fava, Graziella Pinotti(Medica (Italy)), Achille Venco, Anna Teresa Maiolo(Policlinico San Matteo Fondazione), Maria Carla Giorgetti, Gianfranco Pavia(University of Milan), R. Mozzana(University of Milan)
PubMed
December 31, 1996
Cited by 3
Related Papers
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684